Non-Alcoholic Fatty Liver Disease Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with type 2 diabetes
- People aged between 40 and 80 years old
- People who have been found to have fat build-up in the liver (hepatic steatosis), confirmed by a standard abdominal ultrasound scan, as defined by European liver disease guidelines
- People who agree to take part and sign a consent form
- People who are covered by a health insurance plan
Who may not be able to join:
- People who have been diagnosed with cirrhosis (severe liver scarring), confirmed either by a liver biopsy showing the most advanced stage of scarring (F4), or by MRI scan
- People who have another known cause of chronic liver disease, including: active Hepatitis B infection, previous or current Hepatitis C infection, autoimmune hepatitis, certain autoimmune bile duct disorders, Wilson disease, Alpha-1-antitrypsin deficiency, a condition causing iron build-up in the liver (haemochromatosis), liver damage caused by medications, or a blockage in the bile ducts
- People who have taken medications known to cause liver fat build-up in the six months before the study
- People with a known history of cirrhosis or signs of serious liver complications such as fluid build-up in the abdomen, confusion related to liver failure, or enlarged veins in the food pipe
- People who have drunk alcohol regularly or heavily (more than 30g per day for men, or more than 15g per day for women) for more than two years at any point in the last ten years
- People who are pregnant or currently breastfeeding
- People whose life expectancy is less than 5 years
- People with a known HIV infection
- People who have type 1 diabetes
- People with a BMI of 45 or above
- People who are under legal guardianship or supervision due to mental health reasons
- People who are currently detained or deprived of their liberty
- People who do not understand French or are unable to give informed consent
- People who are already taking part in another clinical trial that could interfere with this study, or who are within an exclusion period following a previous trial
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 4 78 86 44 48
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Progression of MASLD for T2D and MASLD patients without AF at baseline (cohort A) or progression to confirmed diagnosis of cirrhosis for T2D and MASLD patients with presence of AF at baseline and without cirrhosis (cohort B).
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.